ArticleInternational journal of STD & AIDS2026
Ending Tuberculosis through prevention: Zimbabwe's PEPFAR Tuberculosis preventive treatment scale-up journey (2016-2024).
Article in International journal of STD & AIDS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
BackgroundTuberculosis (TB) is the leading cause of death among people living with HIV (PLHIV). Globally in 2023, an estimated 161,000 PLHIV died of TB. TB preventive treatment (TPT) can reduce TB mortality yet scale up remains a challenge. We documented Zimbabwe's experience in scaling TPT among PLHIV.MethodologyWe analyzed routine aggregate data from the President Emergency Plan for AIDS Relief (PEPEFAR) database, Data for Accountability Transparency and Impact Monitoring (DATIM). We conducted a desk review of national guidelines, reports, training manuals, policy and strategic plans. Program reports were reviewed to understand scale up best practices, successes and challenges.ResultsTPT coverage (cumulative number completed TPT divided by PLHIV on ART) increased from <1% (144/950,235) in 2018 to 101% (1,040,460/1,029,583) in 2024, in PEPFAR supported health facilities. Adults had a higher TPT coverage of 102% (1,006,544/990,818) than children 87% (33,916/38,765). TPT completion (number started TPT divided number completing TPT) was significantly higher among adults, 99.2% compared to children, 97.9%, difference 1.2 percentage points (CI 0.98-1.50,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.